x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0231245
| Product Information | |
|---|---|
| CAS No. | 330981-72-1 |
| Formula | C13H14BrN3O |
| Molecular Weight | 308.17 |
| Target | GPR119 |
| Product Description | AS1269574 is a potent, orally available GPR119 agonist, with an EC50 of 2.5 μM in HEK293 cells expressing human GPR119. AS1269574 activates TRPA1 cation channels to stimulate glucagon-like peptide-1 (GLP-1) secretion. AS1269574 specifically induces glucose-dependent insulin secretion from pancreatic β-cells only under high-glucose conditions. AS1269574 has the potential for the research of type 2 diabetes. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Purity | > 98% |
| Shipping | Shipped on dry ice. |
| Storage | 4 °C, protect from light *In solvent : -80 °C, 6 months; -20 °C, 1 month (protect from light) |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
